AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Bone morphogenetic protein 1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

P13497

UPID:

BMP1_HUMAN

Alternative names:

Mammalian tolloid protein; Procollagen C-proteinase

Alternative UPACC:

P13497; A8K6F5; B2RN46; D3DSR0; Q13292; Q13872; Q14874; Q99421; Q99422; Q99423; Q9UL38

Background:

Bone morphogenetic protein 1 (BMP1), also known as Mammalian tolloid protein or Procollagen C-proteinase, is pivotal in extracellular matrix formation, influencing bone and cartilage development, muscle growth, and tissue repair. It processes precursor proteins into mature enzymes or structural components, crucial for physiological functions.

Therapeutic significance:

BMP1's involvement in Osteogenesis imperfecta 13, characterized by bone fragility and recurrent fractures, underscores its therapeutic potential. Understanding BMP1's role could open doors to innovative treatments for bone disorders and improve quality of life for affected individuals.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.